Immix Biopharma (NASDAQ:IMMX) Lowered to “Sell” Rating by Wall Street Zen

Immix Biopharma (NASDAQ:IMMX) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Sunday.

A number of other analysts also recently weighed in on IMMX. Mizuho assumed coverage on Immix Biopharma in a research note on Monday, February 9th. They issued an “outperform” rating and a $14.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a report on Thursday, January 22nd. Finally, Citizens Jmp initiated coverage on shares of Immix Biopharma in a research report on Monday, March 9th. They set an “outperform” rating and a $23.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $15.00.

Immix Biopharma Stock Down 1.1%

Shares of NASDAQ:IMMX opened at $10.00 on Friday. The company has a 50-day moving average price of $6.87 and a 200 day moving average price of $4.76. Immix Biopharma has a 52 week low of $1.34 and a 52 week high of $10.71. The company has a market cap of $529.60 million, a P/E ratio of -12.99 and a beta of 0.25.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Janus Henderson Group PLC purchased a new stake in shares of Immix Biopharma in the 4th quarter worth about $20,471,000. Eventide Asset Management LLC acquired a new position in Immix Biopharma during the fourth quarter worth about $13,331,000. Marshall Wace LLP grew its position in shares of Immix Biopharma by 3,495.4% in the fourth quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock valued at $10,349,000 after purchasing an additional 1,923,708 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Immix Biopharma during the 4th quarter worth approximately $8,681,000. Finally, Adage Capital Partners GP L.L.C. purchased a new position in shares of Immix Biopharma during the 4th quarter worth approximately $7,845,000. Institutional investors and hedge funds own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.